Direct Stent, no clinical utility in patients undergoing elective

 Original title: The Independent Value of a Direct Stenting Strategy on Early and Late Clinical Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention. Reference: Gabriel L. Sardi et al. Catheterization and Cardiovascular Interventions 81:949–956 (2013).

 

The use of direct stenting (DS) without pre-stenting dilation has proven to be a safe strategy, especially with the advances that have been achieved in the profile of the new generation devices. In theory, the incidence of peri-procedural myocardial injury and no-reflow phenomenon would be lower given the slightest chance of distal embolization and wall damage compared to pre systematic dilation. In this study, the decision regarding what strategy to use was at the discretion of the operator, so that propensity score was used to match the differences in baseline characteristics of both groups, which left 444 patients in each branch for the final analysis. 

The primary endpoint of the analysis was the extent of myocardial injury peri-procedural according to the elevation of CK-MB. The indicative variables of the use of resources such as procedure time, contrast volume and post dilatation balloons used were significantly higher in pre branch dilatation. The peri-procedural myocardial injury was virtually identical in both groups, (5.3% versus PD SD 5.4%, p = 0.91), as was the incidence of death, myocardial infarction, revascularization or a combination of all (MACE). 

Conclusion: 

In the context of elective angioplasty, a direct stenting strategy reduces procedure time and resource utilization but has no demonstrable clinical benefit at one year. 

Editorial comment: 

The mere fact of diminishing resources, and therefore costs, seems to be reason enough to use direct stenting. Perhaps the most important aspect is correctly judging the injury before starting and choosing a strategy according to the anatomical complexity. These results should not be extended to studying patients with acute coronary syndrome

SOLACI

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...